新型抗体偶联药物和联合疗法在尿路上皮癌中的应用：2023 年 ASCO-GU 癌症研讨会最新进展。
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
机构信息
Department of Urology, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China.
Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning, People's Republic of China.
出版信息
J Hematol Oncol. 2023 Jul 28;16(1):85. doi: 10.1186/s13045-023-01475-9.
Antibody-drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new developments and innovations in the treatment of urological tumors are introduced at the American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. In this article, we summarize some of the most impressive advances in new clinical trials and clinical data on ADCs in the 2023 ASCO-GU Cancers Symposium for the treatment of urothelial carcinoma.
抗体偶联药物（ADCs）将小分子药物的细胞毒性与抗体靶向相结合。由于其精确而强大的作用，它们已成为抗肿瘤抗体药物研发的新热点和重要趋势。每年，在美国临床肿瘤学会-泌尿生殖系统（ASCO-GU）癌症研讨会上都会介绍泌尿肿瘤治疗方面令人兴奋的新进展和创新。本文总结了 2023 年 ASCO-GU 癌症研讨会上关于用于治疗尿路上皮癌的 ADC 的一些最令人印象深刻的新临床试验和临床数据方面的进展。
Zotero 插件